Phase Ii Study Of The Oral Hypoxia-Inducible Factor 2 Alpha (Hif-2 Alpha) Inhibitor Mk-6482 In Combination With Cabozantinib In Patients With Advanced Clear Cell Renal Cell Carcinoma (Ccrcc)

Scott S. Tykodi,Todd Michael Bauer,David F. McDermott,Edward Arrowsmith,Naseem J. Zojwalla,Toni K. Choueiri

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 1|浏览0

暂无评分

摘要

TPS766Background: Although targeting the vascular endothelial growth factor (VEGF) pathway is a valuable therapeutic option for treating advanced ccRCC, response rates are modest and patients event...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要